- Generation of scientific evidence related to fertility across Africa
JOHANNESBURG, South Africa-/African Media Agency(AMA)/- Merck, a leading science and technology company, today announced the signature of a Memorandum of Understanding (MoU) with the African Federation of Fertility Societies (AFFS). Through this agreement, both organisations will jointly work on an agenda to further develop educational training programs for healthcare professionals, aimed at improving access to high quality infertility care in Africa for the ultimate benefit of patients.
By combining their forces, both will benefit from each other’s networks and communication channels, while also exploring opportunities to jointly offer in-depth training programs such as preceptorships and fellowships as well as training courses related to fertility issues for health care professionals. ”We are looking forward to this new collaboration with AFFS, to intensify the exchange and partnership. It will ultimately lead to an important improvement for patients, namely couples who need support to realise their family wishes - which is our common goal. Merck has a long- term commitment and a successful leadership history in reproductive medicine” said Dr. Matthias Meergans, Medical Head MEAR at Merck Healthcare.
Furthermore, the collaboration will focus on other areas such as disease awareness campaigns and generation of scientific evidence facilitating access to high-quality care, starting with the support of the African Network and Registry for Assisted Reproductive Technology (ANARA). Professor Gamal Serour, President of African Federation of Fertility Societies stated that “AFFS welcomes and appreciates collaboration with Merck for the implementation of quality fertility service for the infertile people across Africa”.
-Ends-
Distributed by African Media Agency (AMA) on behalf of Merck.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
Press Contact:
Mantis Communications
Kerry Simpson
Tel: 079 438 3252
Email: kerry@mantiscomms.co.za
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
